148 related articles for article (PubMed ID: 9619024)
1. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
[TBL] [Abstract][Full Text] [Related]
2. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.
Goto H; Usui M; Wakamatsu K; Ito S
Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
4. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
7. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
8. [Significance of 5-S-cysteinyldopa on primary malignant melanoma of the female genital organs].
Takehara M; Mizuuchi H; Ito E; Hayakawa O; Takashima S; Nei H; Kudo R; Horikoshi T; Ito S
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Mar; 44(3):369-72. PubMed ID: 1607763
[No Abstract] [Full Text] [Related]
9. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels.
Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T
Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166
[TBL] [Abstract][Full Text] [Related]
11. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
12. Local environmental influences on uveal melanoma: vitreous humor promotes uveal melanoma invasion, whereas the aqueous can be inhibitory.
Canovas D; Rennie IG; Nichols CE; Sisley K
Cancer; 2008 Apr; 112(8):1787-94. PubMed ID: 18300240
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
14. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
[TBL] [Abstract][Full Text] [Related]
15. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma.
Dunavoelgyi R; Funk M; Sacu S; Georgopoulos M; Zlabinger G; Zehetmayer M; Schmidt-Erfurth U
Retina; 2012 Jul; 32(7):1373-84. PubMed ID: 22418780
[TBL] [Abstract][Full Text] [Related]
16. Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.
Usui Y; Tsubota K; Agawa T; Ueda S; Umazume K; Okunuki Y; Kezuka T; Yamakawa N; Goto H
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):393-399. PubMed ID: 27878431
[TBL] [Abstract][Full Text] [Related]
17. Malignant uveal melanoma and simulating lesions: MR imaging evaluation.
Mafee MF; Peyman GA; Grisolano JE; Fletcher ME; Spigos DG; Wehrli FW; Rasouli F; Capek V
Radiology; 1986 Sep; 160(3):773-80. PubMed ID: 3737917
[TBL] [Abstract][Full Text] [Related]
18. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
19. 5-S-cysteinyldopa in urine and tumors.
Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
[TBL] [Abstract][Full Text] [Related]
20. Clinical, pathologic, and imaging features and biological markers of uveal melanoma.
Rashid AB; Grossniklaus HE
Methods Mol Biol; 2014; 1102():397-425. PubMed ID: 24258990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
